Geoff Green, Longeveron
August 13, 2021 07:59 AM EDTUpdated 02:44 PM
Cell/Gene Tx

Longeveron's cell ther­a­py flops ear­ly walk test study as ex­ecs tout flim­sy sup­port­ing da­ta

Kyle Blankenship

Mi­a­mi biotech Longeveron has sold it­self to in­vestors on the promise of us­ing cell ther­a­py to im­prove the lives of ag­ing pa­tients un­able to walk …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

A service from the Financial Times